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ABSTRACT
In this article, we review the extant social science and
ethical literature on three-dimensional (3D) bioprinting.
3D bioprinting has the potential to be a ‘game-changer’,
printing human organs on demand, no longer
necessitating the need for living or deceased human
donation or animal transplantation. Although the
technology is not yet at the level required to bioprint an
entire organ, 3D bioprinting may have a variety of other
mid-term and short-term beneﬁts that also have positive
ethical consequences, for example, creating alternatives
to animal testing, ﬁlling a therapeutic need for minors
and avoiding species boundary crossing. Despite a lack
of current socioethical engagement with the
consequences of the technology, we outline what we
see as some preliminary practical, ethical and regulatory
issues that need tackling. These relate to managing
public expectations and the continuing reliance on
technoscientiﬁc solutions to diseases that affect high-
income countries. Avoiding prescribing a course of action
for the way forward in terms of research agendas, we do
brieﬂy outline one possible ethical framework
‘Responsible Research Innovation’ as an oversight model
should 3D bioprinting promises are ever realised. 3D
bioprinting has a lot to offer in the course of time
should it move beyond a conceptual therapy, but is an
area that requires ethical oversight and regulation and
debate, in the here and now. The purpose of this article
is to begin that discussion.
BACKGROUND: ‘GROW YOUR OWN ORGANS’
Recent media headlines suggest that scientists will
in the future have the ability to create or ‘biofabri-
cate’ personalised organs such as livers and hearts
through a process known as three-dimensional (3D)
bioprinting.1–3 This is the biological variant of the
recent trend towards 3D printing; small-scale
manufacturing of computer-designed forms
through laying down successive layers of material
until the entire object is created. This development
draws on longstanding printing technology, which
after the invention of the printing press in the 15th
century made books, and thereby knowledge,
widely available and affordable. Later in the 20th
century with the development of the photocopier
and inkjet printers, the hardware component was
set. While 3D printing is working with inorganic
materials, the intention of bioprinting is to work
with organic materials (including living cells) to
create structures approximating body parts.
Specialised bioprinters use biological inks (bioinks
—such as differentiated, human embryonic or
induced pluripotent stem cells (iPSCs)) to print 3D
constructs composed of living organic materials.
These new forms of printing, should they be rea-
lised, will, it is argued, have the same revolutionary
and democratising effect as book printing in their
applicability to regenerative medicine and industry.
Individually designed biological structures or body
parts will become as available as text in modern lit-
erate societies.
There are obvious links drawn between 21st
century 3D bioprinting and the development of the
15th century printing press in terms of process as
well as similarities in the nascent development
stages regarding the effect of resources and access
for both printing technologies.
Long-term 3D bioprinting has the potential to be
a ‘game-changer’, providing an alternative source
of organs no longer necessitating the need for
living or deceased human donation as human
organs would be printed on demand. Nonetheless,
there are key differences between printing and 3D
bioprinting. The latter is distinctive in terms of the
technological process of printing, the organic pro-
ducts that are involved, the therapeutic purpose
and, ﬁnally, in terms of placing the printed organ
within a human body. The technology is not yet at
the level required to bioprint an entire organ. A
realistic and short-term goal is for 3D bioprinting
to create alternatives to animal testing. For
example, drug testing can be accomplished via bio-
printed structures embedded within lab-on-a-chip
devices and even improved by the dramatic increase
in throughput the technology enables.4–6
Furthermore, a mid-term gain still to be realised
however, relates to the creation of tissue compo-
nents such as human heart valves, especially for
younger members of the population (eg, paediatric
patients) who suffer speciﬁc problems with current
bioprosthetic or mechanical heart valve (MHV)
options. The required tissue components are
created from the patient’s own cells (thus reducing
the risk of rejection) and the geometry (size and
shape) of the components can be customised to
match perfectly with the patient’s requirements.
Unlike mechanical implants, such engineered tissue
components that are 3D bioprinted have the ability
to grow with the patient, eliminating the need for
further operations to replace components which
are no longer suitable.7
Given the promise of the technology to solve
entrenched ethical issues relating to supply and
demand of human or non-human animal trans-
plants, a thorough review of any speciﬁc
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socioethical pitfalls is instructive. In order to scope the existing
social science literature in the ﬁeld of bioprinting, literature
searches of articles and book references were undertaken on the
databases PubMed, Web of Science and JSTOR in March and
April 2016, and undertaken again in June 2016 in order to iden-
tify any extra articles (ﬁgure 1). In addition to this, the Institute
of Physics journal Biofabrication was searched as a leading
journal in this area of biofabrication and bioprinting. This
review exercise found that with only a few notable exceptions
from the areas of law or social sciences,8–15 the current literature
on bioprinting speciﬁcally (rather than traditional 3D printing)
is located entirely within the biological sciences and medical
sciences. Much of the medical and scientiﬁc literature, however,
does focus on some social aspect of the technology within dis-
cussion to some extent. This allows analysis of both what is
already being highlighted within scientiﬁc articles, and allows
the identiﬁcation of areas where social science research might
build on existing themes or ﬁll gaps in understanding. The latter
we will address through offering both positive and negative ana-
lysis of the socioethical challenges that might lie ahead.
Although bioprinting can avoid ethical dilemmas associated
with xenotransplantation and clinical organ transplantation, it is
not without its own challenges, practical, ethical and regulatory,
which we will need to address. These relate to managing public
expectations and the ethics of biomedicine’s continuing reliance
on costly technoscientiﬁc solutions. For example, the expense of
creating your own personalised organ may mean that waiting lists
are the equivalent of waiting on an allograft or human transplant.
As such, it seems important to explore possible scenarios of
3D bioprinting and its applications for tissue and organ creation.
Hence, we hope to begin discussion with a modest contribution.
After outlining extant literature and given we found little ethical
or social commentary from an arts, social science and humanities
perspective, we offer a comparative ethical analysis weighing up
a few of the beneﬁts and challenges 3D bioprinting may cause
should its promise be realised. There are different frameworks
for engaging with social science and ethical aspects of new
technologies and we outline and discuss whether Responsible
Research Innovation (RRI), currently favoured, may be a way to
deal with and reﬂect on 3D bioprinting, especially around inter-
disciplinary ethics. 3D bioprinting may have a lot to offer in the
course of time, but as an area, it needs ethical oversight and
regulation as well as debate. A debate we hope to begin.
3D BIOPRINTING AND BIOFABRICATION
3D printing is undoubtedly proven successful and 3D printers
are now widely used and commercially available. Bioprinting as a
particular area regularly discussed in both academic literature
and the media in connection alongside 3D printing techniques
that use non-biological materials (eg, plastics, metals, fabrics or
ceramics). 3D printing of objects has rapidly developed from
being a niche and expensive development on two-dimensional
(2D) printing technology in the 1980s to now being an extremely
rapidly developing industry with ever-increasing applications.
Bioprinting is a far more complex matter, which is explored
in the emerging ﬁeld of biofabrication. Although the terms bio-
printing and biofabrication are often used interchangeably and
do overlap, the most up-to-date deﬁnition is offered which
delineates between natural biomineralisation (eg, pearls) and
technological biofabrication: bioprinting and bioassembly. The
latter, used for tissue engineering and regenerative medicine, is
described as the:
… the automated generation of biologically functional products
with structural organization from living cells, bioactive molecules,
biomaterials, cell aggregates such as micro-tissues, or hybrid cell-
material constructs, through Bioprinting or Bioassembly and sub-
sequent tissue maturation processes.16
And bioprinting as deﬁned in Oxford dictionary:
The use of 3D printing technology with materials that incorpor-
ate viable living cells, for example, to produce tissue for recon-
structive surgery.17
At the moment, biofabrication exhibits many elements of an
emerging new community in science,18 including an annual con-
ference, an international society for biofabrication, several jour-
nals and new educational programmes at universities around the
world. Biofabrication and the subdivision of bioprinting
connect closely to the large and multidisciplinary areas of tissue
engineering and regenerative medicine in both their techniques
(the use of biological materials to build constructs) and in the
goal of using the body’s own processes to replace and regenerate
the body. Scientists trace back the start of bioprinting to over
three decades ago, with the appearance of articles that started to
explore the possibilities to organise cells spatially into structures
that closely mimic the native tissue architecture and can poten-
tially help to fabricate engineered tissue.19–21
A primer into bioprinting distinguishes different approaches,
technologies and materials.22 First, different printing technolo-
gies are used, including inkjet, bioextrusion, laser-assisted bio-
printing and valve-based techniques. Second, different forms of
bioprinting are distinguishable: rational design and autonomous
self-assembly. While biomimicry aims to manufacture identical
reproductions of cellular and extracellular components of tissue
or organs through rational design, autonomous self-assembly
Figure 1 Literature search sources for social science literature on
biofabrication undertaken in March–June 2016.
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takes embryonic organ development as a guide, replicating tissue
by relying on the capacity of cell(s) to generate functional and
structural properties of tissue through self-organisation. Building
on these two processes, organoids, the functional building blocks
of tissues and organs, are constructed. For such tissue engineer-
ing, pluripotent stem cells (PSCs) are the favoured cells to use
given their ability to both self-renew and differentiate into any
required adult cell type4; this means that PSCs can be expanded
into the large numbers required and then programmed to differ-
entiate into the required organ-speciﬁc cell lines. Unlike primary
cells, which have a limited number of expansion cycles, PSCs are
divided into embryonic stem cells (ESCs) and iPSCs. The ethics
of using ESCs remain controversial in some countries, especially
those such as the USA where the use is heavily restricted.
Although ESCs are quite commonly used, adults’ own cells are
reprogrammed into iPSCs for use. Ideally, the use of iPSCs can
overcome any problems of an immunological response to the
bioprinted organ. Induced-PSCs have not been inserted into a
human being in this way and the risks of doing so currently incal-
culable. Moreover, in addition to the cells that are chosen to
print with, it is crucial to pick the right medium in which to
suspend the cells (of multiple different cell types) or scaffold
material for the printing process, such as natural polymers or
synthetic hydrogels to support bioprinting of 3D structures.
POSSIBLE SHORT-TERM BENEFITS OF 3D BIOPRINTING
Short-term beneﬁts of avoiding animal testing
As previously mentioned, there are short-term goals that can be
accomplished with the development of 3D bioprinting.
Short-term applications could relate to drug testing (thereby
reducing the need for animal testing) as testing of drugs could
take place on ‘organ-on-a-chip’ technologies. A person’s own
cells can be reprogrammed into iPSCs, which can be used to
generate bioprinted organoids that test the potency and efﬁcacy
of pharmaceutical drugs. Potentially, this offers a more ethical
process than the use of animals for drug testing and a more efﬁ-
cient and reliable one as the testing is done on human tissues.
Indeed, there is the further potential for personalised medicine,
where a particular individual’s reaction to a drug can be gauged
alleviating the incidence of adverse drug reactions and dosages
can be adjusted to suit the required efﬁcacy.
Short-term beneﬁts of tissue engineering
Apart from the ‘personalised medicine’ opportunities offered
by 3D bioprinting, robust technological advances are made in
terms of the tissue engineering. Artiﬁcial skin, cartilage and
tracheas have been tissue engineered,23 and there have been
advances in work on the printing of bone,24 parts of the ear11
and of heart valves.25 Bladders have been ‘moulded’ and suc-
cessfully implanted into a patient.26 However, all of these are
relatively simple structures and such techniques are not easily
(if at all) transferrable to engineering complex solid organs,
which are more applicable for drug testing applications and
more in demand for organ replacement4 (http://www.nhsbt.
nhs.uk/).
Short-term beneﬁts of disease modelling
Another possibility exists if instead of healthy tissue were to be
bioprinted, one could add cancerous tissue and disease models27
in order to study the efﬁcacy of novel treatments outside
the patient’s body. By incorporating the patient’s own cells
more accurate models and hence more effective treatments
should result.
POSSIBLE LONG-TERM BENEFITS
Long-term beneﬁts: avoiding the animal question
Although yet to succeed, researchers are now working on the fab-
rication of solid 3D organs.28 29 Regenerating human organs is
potentially a game-changer in the volume and process of repair-
ing and replacing human organs. Bioprinting may be more ethic-
ally robust than genetically altering and then growing organs in
host animals. Chimaera pigs bring into question how such scien-
tiﬁc objects can be ethically regulated when it is difﬁcult to clas-
sify what is human or what is animal.30 Further rising attention is
given to the status of non-human animals. The term ‘non-human’
animals refers to the increasing recognition that some animals
share cognitive and emotional characteristics with humans. Public
attitudes demonstrate that although participants suggested it was
‘morally acceptable’ to develop and research xenotransplant-
ation,31 only 77% of the Swedish public were willing to accept
an organ from a relative, 69% from a deceased person, 63% an
artiﬁcial ‘organ’ and 40% an animal organ.25 32 From empirical
sociological research available, the mixing of animal and human
materiality produces public reactions of disgust or ‘yuck’.33–36
Unlike xenotransplantation, which remains highly experimental
despite advances using CRISPr technology to modify porcine
hearts in order to prevent rejection, 3D printing organs circum-
vents intractable problems relating to source and process.
Long-term beneﬁts: avoiding the possibility of ‘yuck’
Shaw et al37 have argued how chimaera pigs, used to incubate
human organs created through the implantation of iPSCs, can
be an ethical source of immunocompatible organs. While this is
indeed a good parallel development, bioprinting seems an
attractive alternative as it avoids the ‘yuck’ factor.33 36 The
descriptive basis of using the ‘yuck’ factor as originally discussed
by Kass38 has been expanded as a normative one to ask ques-
tions such as whether the ‘yuck’ factor should be used as the
basis for social and ethical debates or institutionally forma-
lised.39 Our intention here is not to challenge the usefulness of
the concept in ethical or legal debates but to state that, as a
social reaction, it exists as an emotion regardless of whether or
not it ought to be involved in moral judgements.39 The ‘yuck’
response is, as Mary Douglas argues, linked to ideas about
‘Pollution behaviour’ the reaction which condemns any object
or idea likely to confuse or contradict cherished classiﬁcations’
as out-of-place.36 40 Hence, although ethicists and philosophers
have argued that the normative power of ‘disgust’ is limited and
can do no moral work, others have found it a powerful way to
discuss how social attitudes are reacting to the way that technol-
ogy is challenging what is presumed as natural:
The contemporary need for naturalness can be better understood
as a response to the fact that technology makes reality more and
more makeable and, consequently, more contingent. Advancing
technology changes everything that is, into our object of
choice…[I]f human nature itself becomes makeable, it can no
longer naively be laid down as the norm.41
The Nufﬁeld Council of Bioethics (2015)42 in a recent analysis
of the role ‘natural’ plays in public debate argues that it is a term
best be avoided because of the variability in its use over time. We
suggest that 3D bioprinting avoids all debates about yuck and
what is natural and hence is likely to be more ethically robust in
terms of social acceptability than other areas of biotechnologies.
Long-term beneﬁts: end the ﬁnancial costs in human organs
Evidence suggests that the human organ transplantation rates
have plateaued and indeed is a victim of its own technological
Vermeulen N, et al. J Med Ethics 2017;0:1–7. doi:10.1136/medethics-2015-103347 3
Global medical ethics
group.bmj.com on April 11, 2017 - Published by http://jme.bmj.com/Downloaded from 
success; as a greater range of organs can be transplanted, more
organs will be needed. And for organs that are not paired and
cannot come from living donors, organs rest on an ethically
double-edged sword; in order to save life another person has
died. Organ regeneration would eliminate the need for human
organs and therefore in the long run also reduce the medical
costs associated with transplantation.8 It could also end the
illegal trade in organs and human abuses that occur with it.43
Long-term beneﬁts: with immediate ‘youth’ value
Organs for young adults and children have always been difﬁcult
to procure for all the reasons stated above as well as having to
come from a young donor. Some applications of 3D printing
may in the future be primarily directed at a young age cohort
given young people’s suitability to receive a bioprinted
replacement organ as their bodies can grow around with the
organs.44–46 Equally, younger individuals who suffer from heart
valve disease can have issues relating to using bioprosthetic heart
tissue valves. Such valves from porcine sources only last as long
as the pig donor would have done; approximately 10–15 years
and therefore, the tendency is to use them with older patients.
Using MHVs last longer but with the side effects of a lifetime
on anticoagulants for younger recipients. The ‘appeal’ then of
3D bioprinting, or of ‘here is one made earlier’ is a much more
attractive option than a lifetime on medication.
BIOPRINTING—ETHICAL CHALLENGES
There has been little discussion of risks in the social science or
ethics literature that we have found; hence, this can lead to
assumption that there are no risks. Moreover, knowledge of opi-
nions, views and attitudes of publics and patients is essential in
an area where little is understood. Therefore, we will use the
rest of this article to outline ethical and social issues and ways to
explore them further.
Ethical challenge: social stratiﬁcation of bioprinting
The promise or the hype of print your own organs is the most
attractive solution to organ replacement avoiding sociocultural
issues relating to possible breaches of interspecies and intraspe-
cies integrity. For example, since the ﬁrst human heart transplant
narratives of some form of donor identity persisting and effecting
the recipients, the regeneration of ‘self-organs’ will eliminate
reported incidences of recipient changes in behaviour, identity
and preference.47 Yet, the promise and hype is out of proportion
to the possibility of realising 3D bioprinting and even in the pos-
sibility that 3D bioprinting was made a reality, it raises again the
ethics of an increasing reliance on high sociotechnical solutions
to middle-income country diseases. These are expensive technos-
cientiﬁc solutions likely to beneﬁt only a few members of a par-
ticular subgroup (and brings to the fore of accessibility that needs
addressing for regenerative medicine and tissue engineering).
Therefore, 3D bioprinting is another solution that will not be a
game-changer for everyone and certainly not for most in its
immediate applications. Despite the promise of organs printed
on demand for all, it is likely that the spectre of a ‘social stratiﬁca-
tion of biofabrication’ will emerge, with those who can afford to
pay for their ‘own’ organs beneﬁtting. A tiered system of thera-
peutic organ replacement is likely with those who can afford to
pay for self-organs living longer; perhaps enjoying a signiﬁcantly
high quality of life avoiding the negative physical consequences
of taking immune-suppressant drugs. While others will wait until
a human organ donor becomes available and then have to under-
take a punishing drug regime for the rest of their lives to prevent
episodes of rejection of the transplanted organ. Others who
cannot afford to pay then will make do with ‘second-hand’
organs from another living or deceased donor once available (as
is the current system).
Ethical challenge: managing expectations: avoiding the hype
It is important to note that while 2D bioprinting (tissues such as
skin) and hollow tube printing (such as blood vessels and heart
valves) are simpler, and therefore are more achievable on a
short-term timeframe, hollow organs (such as the bladder) and
solid organs (such as the liver and kidney) are far more complex
and will require long-term development.22 Scientists are unable
to put forward a concrete timeframe, due to the unpredictability
of various challenges that need to be overcome. Indeed, it is a
matter of some debate whether an organ can be successfully
printed. Regarding organs one would have to print the organ
and all the complex vasculature within it. As Mironov et al48
suggest, ‘[A]chieving the desired level of cell density, effective
vascularisation and accelerated tissue maturation are remaining
challenges’. Problems also persist at the level of granularity.
Indeed they have suggested that:
The only economic and reasonable way to commercialize organ-
printing technology is to systematically employ scalable auto-
mated robotic technology and to build an integrated organ bio-
fabrication line. It is not sufﬁcient to develop just one robotic
device—a bioprinter…[it] will require the development of series
of integrated automated robotic devices, or an organ biofabrica-
tion line.48
Ethical challenge: ethics of untested paradigms: living cells
3D bioprinting remains an untested clinical paradigm and is
based on the use of living cells placed into a human body; there
are risks including teratoma and cancer, dislodgement and
migrations of implant. This is risky and potentially irreversible.
Most studies showed short-term success; however, more long-
term in vivo studies are required to show if side effects may
emerge. Obviously, the need for cell source for bioprinting
raises ethical issues around ESCs, in line with more common
debates on their use. Despite promises of personalised medicine
where adverse drug reactions can be tested by an
‘organ-on-a-chip’ technology, and therefore offer ‘cruelty-free
drug testing’, how can medicine that is so highly personalised be
then social stratiﬁed to the rest of the population? Who would
be ﬁrst in trial for example?
Ethical challenge: ownership of printed bio-objects
Legal offerings suggest that bioprinting enters new territory dis-
tinct from previous legal regulation on medicine or on conven-
tional 3D printing in relation to legal ideas of the body and the
rights and responsibilities held by different groups.9 10 12 13
Harbaugh9 focuses mainly on issues around ownership and the
potential value of bioprinting products to different interested
parties, including physicians, researchers and biotechnology
companies. This is accompanied by a duty, however, to maintain
the patients’ autonomy over their bodies. It is similarly sug-
gested by Tran12 that beneﬁts of bioprinting outweigh what he
considers to be comparatively low risks, but that joint regulation
between the medical and legal professions is needed to prevent
new forms of exploitation such as a new black market in biofab-
ricated organs.
The article by Li10 looks in further depth at potential intellec-
tual property frameworks for bioprinting. An important distinc-
tion she raises relates to whether bioprinters should be
categorised as machines used for a medical purpose, and thus a
patentable entity, or non-patentable medical techniques
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involving direct printing onto or into the body, and thus not
possible to be patented through the legal ‘medical treatment
exception’. Similarly, products must pass the ‘morality test’ that
it is morally acceptable to patent the item or process. These
legal conditions in themselves raise pertinent ethical questions
about the nature of bioprinted products—should they be
regarded more as a type of (proﬁtable) technology, or as a skill/
treatment of the future? Organisations such as the United States
Food and Drug Administration have also faced complexity when
categorising bioprinted materials.13
Were the conditions for patenting of bioprinting to be satis-
ﬁed, Li highlights potential dangers when it comes to the mon-
opoly of particular scientiﬁc innovations stiﬂing further
innovation and also meaning that access to scientiﬁc beneﬁts can
be grossly unequal, which relates to this article’s previously dis-
cussed fears of social stratiﬁcation. However, others such as
Varkey and Atala also highlight intellectual property provisions
as able, from a scientiﬁc perspective, to protect the various steps
of the bioprinting process.13 With many parallels to the current
paper’s later suggestion of the need for RRI, Li makes her own
suggestion of a ‘portfolio approach’ to legal licensing in bio-
printing.10 This places responsibility on companies to share ben-
eﬁts as well as emphasising the key role of publicly funded
research.
Reﬂections are required on the kind of objects that could be
created. What are bioprinted organs, how can we think about
them and categorise them while they are crossing the conven-
tional boundaries between life and non-life, for example, as
bio-object49 or active matter (http://activemattersummit.com)?
Questions arise about whether a reﬁnement of current legisla-
tion or the introduction of new legislation, for example, how to
deal with a hybrid bio-object? To whom do 3D bioprinted
organs belong, and who has the right and/or opportunity to
grow their own?
Governance and regulations: responsible research and
innovation
As demonstrated, social science and ethics might occupy a gap
when it comes to issues around the development and produc-
tion of 3D bioprinted organs. Wang et al50 argue that:
[A]s a new topic of study, safety guidelines have not been ﬁrmly
established in this ﬁeld. The side effects of bioprinting have
rarely been addressed, including questions such as biomaterials
degradation and tissue integration, biocompatibility, and continu-
ous tissue synthesis during material degradation.
Similarly, Guillemot et al17 bring attention to data protection
in the context of bioprinting. Therefore, we do not prescribe a
research agenda for future work but modestly highlight the
need for one. Furthermore, there is a variety of ways that gov-
ernance of 3D bioprinting might be discussed. In conclusion,
we highlight one such framework.
As an emerging ﬁeld of study, the way in which science policy
and research funding are stimulating biofabrication in general,
and speciﬁc lines of research within bioprinting in particular is
fundamental. Obviously, and because of its interdisciplinary
nature, bioprinting requires the building of bridges on different
levels.51 How are current and projected developments redraw-
ing those disciplinary boundaries, in the lab between scientists
with different backgrounds, and in terms of policy and funding?
For example, in the British context, bioprinting research
involves collaborations between different funding sources,
cutting across the Biotechnology and Biological Sciences
Research Council (BBSRC), Engineering and Physical Sciences
Research Council (EPSRC), Medical Research Council (MRC)
and National Centre for the Replacement Reﬁnement and
Reduction of Animals in Research (NC3Rs). An important ques-
tion is how such collaboration for biofabrication is best
shaped52? Moreover, and as bioprinted products do not ﬁt
current clinical trials governance,53 existing regulations need to
be rethought and perhaps redesigned to guarantee the safety
that Wang et al50 and Guillemot et al17 ask for.
Towards a new framework to discuss ethics: from ethical
legal social implications to RRI
While opening-up this debate through the outlining of relevant
questions that need to be considered, we also would like to
suggest a way forward in answering them. Similar to the scien-
tiﬁc/technological shift—from regenerative medicine relying on
animals to bioprinting, bringing new beneﬁts and challenges—
there is also a shift taking place in the framework in which
reﬂections on new developments in the (bio)sciences are per-
formed. While genomics came together with research on
ethical, legal and social implications or aspects (ethical legal
social implications (ELSI) and/or ethical legal social aspects
research), there is now a trend towards more upstream ethical
and social engagement through so-called RRI. This new oeuvre
in science policy,54 which developed mainly in the context of
nanotechnology and gains momentum within synthetic biology,
seems to be a proper framework to tackle issues around emer-
ging technologies on the boundary between life sciences and
engineering and on existing approaches, such as constructive
technology assessment. RRI is proposed as the ongoing process
of aligning research and innovation to the values, needs and
expectations of society, which requires that all actors, including
civil society are responsive to each other and take shared
responsibility for the processes and outcomes of research and
innovation.55 By building trust between citizens, and public and
private institutions, and by collectively assessing the risks as well
as the way these risks should be managed, it is hoped that
research outcomes will contribute useful, smart, inclusive and
sustainable solutions to deﬁned societal challenges.
The application of the RRI framework to emerging biotech-
nologies and objects simultaneously builds on and departs from
the previous ELSI approach developed in the context of the
Human Genome Project. It continues ELSI research through
sustaining research into ethical, legal and social dimensions that
emerge through novel developments in the biosciences.
However, it importantly departs from the ELSI reactive stance—
focussing on implications of scientiﬁc research—through the
actual integration of social and ethical research in the scientiﬁc
research practice. This concretely means that scientists and their
social sciences and humanities counterparts are working
together in research projects or centres to continuously interact
and inﬂuence each other’s thinking and the framing of the new
technologies and their applications, while also connecting to
societal actors and different users and publics.
The beneﬁts of this integrative and collaborative approach can
be illustrated through a recent paper which outlines an ELSI
approach to bioprinting.15 In this paper, authors present various
recommendations to discuss 3D bioprinting technologies so it
can be effectively regulated while harvesting its beneﬁts for
public health. We certainly recognise the value of their sugges-
tions to further ethical debate, yet it is important to note that
their recommendations are reactive in the sense that they
emphasise how ethical, legal and social aspects play an import-
ant role in the successful market translation of technologies
(p. 19). Consequently, they do not envision the integration of
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ethicist and social scientist in scientiﬁc practice when the tech-
nologies are collaboratively imagined and potentially realised.
However, and in light of our analysis that identiﬁes a substantive
gap between current practice and potential outcomes, we argue
that the more proactive RRI approach may be a preferred alter-
native framework, as it brings ELSI into the laboratory and sci-
entiﬁc conferences, contributing to its earliest development
stages as well as to their translation.
RRI itself is still very much a concept in development and as
such, we are pursuing collaboration between the scientists
working in the realm of bioprinting and social scientists
working on the emergence and ethics together of 3D bioprint-
ing as exempliﬁed by this article that is collectively authored.56
CONCLUSIONS
The social and ethical challenges around 3D printing have
received little commentary despite the schism between social
promise and progress in technological terms. At ﬁrst sight there
seems less cause for angst as regeneration of human organs is
less ethically fraught when compared with other technoscientiﬁc
solutions such as animal sources. Moreover, the 3D bioprinting
technology could potentially prove to be a game-changer in
terms of how the human body is repaired or replaced.
Nevertheless, there remain issues around general access and
equity, biological and engineering responsibilities in terms of
functionality matching with in vivo organs as well as the ethical
governance of process, object and outcomes.
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